ARONJ: An Update

24
Oct, 2014

This symposium features researchers and clinicians from both Penn Dental Medicine and Penn Medicine and is built on the multidisciplinary interaction between the different specialties engaged in research and clinical management of osteonecrosis of the jaw (ONJ) patients. The program will address gaps in our understanding of how anti-resorptive drugs may interfere with immune function, wound healing, and bone repair, and explore how to bridge these findings in the development of new prevention and intervention strategies for ONJ. The purpose of this course is to provide dentists, physicians, and other health care providers knowledge and clinical skills in diagnosing and managing complications of anti-resorptive-drug-induced osteonecrosis of the jaw (ARONJ).